Search Results - "WOOLLEY, P. V"

Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry by Lesesne, J B, Rothschild, N, Erickson, B, Korec, S, Sisk, R, Keller, J, Arbus, M, Woolley, P V, Chiazze, L, Schein, P S

“…A registry of suspected cases of cancer-associated hemolytic-uremic syndrome (C-HUS) was established in May 1984. Records of 85 patients from the registry, all…”
Get more information

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin by Rahman, A, Treat, J, Roh, J K, Potkul, L A, Alvord, W G, Forst, D, Woolley, P V

“…We have treated 14 cancer patients with liposome-encapsulated doxorubicin (LED) at doses of 30, 45, 60, and 90 mg/m2. Nausea and vomiting, phlebitis, and…”
Get more information

Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study by Treat, J, Greenspan, A, Forst, D, Sanchez, J A, Ferrans, V J, Potkul, L A, Woolley, P V, Rahman, A

“…Previous studies in animals have demonstrated liposome-encapsulated doxorubicin (LED) has substantially less cardiac toxicity than free doxorubicin but retains…”
Get more information

Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion by Korec, S, Schein, P S, Smith, F P, Neefe, J R, Woolley, P V, Goldberg, R M, Phillips, T M

“…Plasma perfusion over filters containing staphylococcal protein A (SPA) was used to treat 11 patients with adenocarcinoma who developed a hemolytic uremic…”
Get more information

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer by MacDonald, J S, Schein, P S, Woolley, P V, Smythe, T, Ueno, W, Hoth, D, Smith, F, Boiron, M, Gisselbrecht, C, Brunet, R, Lagarde, C

“…Sixty-two patients with advanced measurable gastric cancer were treated with a combination chemotherapy program of 5-fluorouracil, doxorubicin, and mitomycin…”
Get more information

Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue by RAHMAN, A, JAE KYUNG ROH, WOLPERT-DEFILIPPES, M. K, GOLDIN, A, VENDITTI, J. M, WOOLLEY, P. V

“…Tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue, showed greater therapeutic efficacy after i.p…”
Get full text

Cancers of the large bowel and hepatobiliary tract by Treat, J, Woolley, 3rd, P V

Get more information

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma by WOOLLEY, P. V, SCHULTZ, C. J, RODRIGUEZ, G. I, GAMS, R. A, ROWE, K. W, DADEY, M. L, VON HOFF, D. D, MCPHILLIPS, J. J

“…We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a…”
Get full text

Cancers of the large bowel and hepatobiliary tract by Treat, J, Woolley, 3rd, P V

Get more information

A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil by Woolley, P V, Ayoob, M J, Smith, F P, Lokey, J L, DeGreen, P, Marantz, A, Schein, P S

“…We have evaluated, in a controlled study, the modification of the toxicity of a single bolus dose of 5-fluorouracil (5-FU) by allopurinol. Patients first…”
Get more information

Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide by Woolley, 3rd, P V, Ayoob, M J, Smith, F P, Dritschilo, A

“…S-2-(3-Aminopropylamino)-ethylphosphorothioic acid (WR-2721) is reported to protect normal tissues from the effects of ionizing radiation and possibly…”
Get more information

Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy by MCCABE, M, SMITH, F. P, MACDONALD, J. S, WOOLLEY, P. V, GOLDBERG, D, SCHEIN, P. S

“…Oral delta-9-tetrahydrocannabinol (THC), 15 mg/m2, was compared to prochlorperazine (PCZ), 10 mg. for the control of cancer chemotherapy-related emesis…”
Get full text

Therapy of advanced gastric carcinoma. The Georgetown-Lombardi Cancer Center experience by Treat, J, Falchuk, S C, Woolley, P V, Ahlgren, J D, Neefe, J R, Smith, F P, Macdonald, J S, Schein, P S

“…Gastric carcinoma, despite a decreasing incidence in the United States over the past 40 years, is the seventh most common cause of cancer death in this country…”
Get more information

Cancers of the large bowel and hepatobiliary tract by Treat, J, Woolley, 3rd, P V

Get more information

Probable Clonal Origin of Acute Myeloblastic Leukemia Following Radiation and Chemotherapy of Colon Cancer by Wiggans, R. Glen, Jacobson, Robert J., Fialkow, Philip J., Woolley, Paul V., Macdonald, John S., Schein, Philip S.

“…A 64-yr-old female developed acute myeloblastic leukemia following radiation and drug therapy for colon carcinoma. The patient was heterozygous for…”
Get full text

Combination chemotherapy for locally advanced pancreatic cancer: equivalence to external beam irradiation and implication for future management by Smith, F P, Stablein, D, Korsmeyer, S, Neefe, J, Chun, B K, Woolley, P V, Schein, P S

“…Chemotherapy with 5-fluorouracil, doxorubicin, and mitomycin-C was administered to 17 patients with locally advanced pancreatic cancer. The median survival for…”
Get more information

Genetic studies on hypospadias in males by Chen, Y C, Woolley, P V

Get full text

Cancers of the large bowel and hepatobiliary tract by Treat, J, Woolley, 3rd, P V

Get more information

5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas by Smith, F P, Hoth, D F, Levin, B, Karlin, D A, MacDonald, J S, Woolley, 3rd, P V, Schein, P S

“…Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C…”
Get more information

Current management of advanced and locally unresectable gastric carcinoma by Schein, P S, Smith, F P, Woolley, P V, Ahlgren, J D

“…Gastric cancer is the most chemotherapy-responsive adenocarcinoma of the major gastrointestinal sites. For patients with advanced disease, the response rates…”
Get more information